Results Of A Double-Blind, Randomized, Placebo-Controlled Study Of Nabiximols Oromucosal Spray As Adjunctive Therapy In Advanced Cancer Patients With Chronic Uncontrolled Pain

Key Findings

Although not superior to placebo on the primary efficacy endpoint, nabiximols had benefits on multiple secondary endpoints, particularly in US patients. Nabiximols might have utility in patients with advanced cancer who receive a lower opioid dose, such as individuals with early intolerance to opioid therapy.

Information and Links

Link: Results Of A Double-Blind, Randomized, Placebo-Controlled Study Of Nabiximols Oromucosal Spray As Adjunctive Therapy In Advanced Cancer Patients With Chronic Uncontrolled Pain

Year: 2017

DOI: 10.1016/j.jpainsymman.2017.09.001